RYBOX — Biotechnology Fund
Data updated: 2026-06-15
RYBOX — Biotechnology Fund data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $135.07M AUM · 1.65% expense ratio · 34.9% 1-yr return. From SEC regulatory filings.
RYBOX Fund Overview
RYBOX — Biotechnology Fund is a US mutual fund managed by Rydex Series Funds, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Rydex Series Funds
- Category: United States Health Care Equity
- Assets under management: $135.07M
- 1-year return: 34.9%
- Ticker: RYBOX
- SEC CIK: 0000899148
- SEC series ID: S000003802
- Share class ID: C000010596
RYBOX Holdings
Top 10 holdings of Biotechnology Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| AbbVie Inc. | 7.39% |
| Amgen Inc. | 5.23% |
| Gilead Sciences Inc. | 4.96% |
| Vertex Pharmaceuticals Incorporated | 4.01% |
| Regeneron Pharmaceuticals, Inc. | 3.56% |
| Alnylam Pharmaceuticals Inc. | 2.60% |
| Insmed Inc | 2.45% |
| Beone Medicines Ltd. | 2.29% |
| Natera, Inc. | 2.09% |
| United Therapeutics Corporation | 2.07% |
RYBOX Portfolio Allocation
Asset-class allocation of Biotechnology Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 98.7% |
| Cash & Equivalents | 0.4% |
RYBOX Performance
Total returns for RYBOX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 2.0% |
| 1 year | 34.9% |
| 3 years (annualised) | 12.5% |
| 5 years (annualised) | 4.5% |
RYBOX Risk Information
Risk metrics for RYBOX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 13.8%
RYBOX Costs and Fees
RYBOX costs about $165 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.65%
- Gross expense ratio: 1.68%
- Portfolio turnover: 51%
- Brokerage commissions: 2.49 bps of average net assets (SEC N-CEN)
RYBOX Cashflows
Over the 12 months to 2026-03, Biotechnology Fund had net inflows of $32.12M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | −$189.18K |
| 2026-02 | −$772.29K |
| 2026-01 | $24.75M |
| 2025-12 | $6.69M |
| 2025-11 | $8.99M |
| 2025-10 | $1.93M |
RYBOX Debt Constituents
No individual debt constituents are reported in Biotechnology Fund's latest SEC N-PORT filing.
RYBOX Prospectus and SEC Filings
Official Biotechnology Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.